NYSE: BLCOBausch & Lomb Corp Stock
$15.91+0.35 (+2.25%)
Updated Mar 24, 2025
BLCO Price
$15.91
Fair Value Price
N/A
Market Cap
$5.61B
52 Week Low
$13.16
52 Week High
$21.69
P/E
-17.68x
P/B
0.87x
P/S
1.33x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.79B
Earnings
-$317.00M
Gross Margin
60.9%
Operating Margin
3.19%
Profit Margin
-6.6%
Debt to Equity
1.07
Operating Cash Flow
$232M
Beta
0.92
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BLCO Overview
Bausch + Lomb Corporation offers contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. It also offers medicines for various eye diseases and irritations and surgical supplies, aids, and implants. Bausch + Lomb was founded in 1853 and is headquartered in Vaughn, Ontario, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BLCO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important BLCO news, forecast changes, insider trades & much more!
BLCO News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BLCO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLCO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BLCO is good value based on its book value relative to its share price (0.87x), compared to the US Medical Instruments & Supplies industry average (3.8x)
P/B vs Industry Valuation
BLCO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BLCO due diligence checks available for Premium users.
Valuation
BLCO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-17.68x
Industry
41.19x
Market
32.57x
BLCO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.87x
Industry
3.8x
BLCO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BLCO's financial health
Profit margin
Revenue
$1.3B
Net Income
-$3.0M
Profit Margin
-0.2%
BLCO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BLCO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.5B
Liabilities
$6.9B
Debt to equity
1.07
BLCO's short-term assets ($2.79B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLCO's long-term liabilities ($5.19B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLCO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$22.0M
Investing
-$185.0M
Financing
$146.0M
BLCO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BLCO vs Medical Stocks
Bausch & Lomb Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.